title: Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches.
abstract: Sumatriptan subcutaneous administration is the fastest and most effective of the triptans for relief of acute migraine headache. This occurs even when the patient has already developed symptoms related to central sensitization, a key parameter in determining the effectiveness of these agents. In patients whose migraine attacks have historically failed to respond to oral triptans, this route of administration has also proven to be more consistent and effective. Until recently this method of drug delivery was dependent upon a needle for administration. A new method of delivery for this agent, Sumavel(®) DosePro™, eliminates the needle and disposal issues coupled with an improved ease of use of drug delivery and acceptable tolerability for patients in clinical trials.
authors.affiliation: Comprehensive Headache Center, Baylor University Medical Center, 9101 North Central Expressway #400, Dallas, TX 75231, USA. dhcdoc@gmail.com
authors.forename: Frederick G
authors.initials: FG
authors.lastname: Freitag
mesh_terms: D003027:Cluster Headache / Q000188:drug therapy* / Q000503:physiopathology; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D058825:Serotonin 5-HT1 Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D058825:Serotonin 5-HT1 Receptor Agonists; D018170:Sumatriptan